Orlando, FL, April 14-19
Meet the Singular team next week at the AACR Annual Meeting Booth 1613 for live demonstrations of the G4 Sequencing Platform and learn how the G4 can transform your research capabilities. Schedule a meeting with a member of the team now!
Featuring novel, high-performance chemistry and advanced engineering, the G4 Sequencing Platform has been optimized to deliver speed, power, unprecedented flexibility, and accuracy.
Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.
Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.
